Phase II Trial of Anti-HER-2 Monoclonal Antibody Trastuzumab (Herceptin) in Combination With Low Dose Interleukin-2 (Proleukin) in Metastatic Breast Cancer Patients Who Have Previously Failed Trastuzumab
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2015
At a glance
- Drugs Aldesleukin (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 14 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Sep 2005 New trial record.